Skip to content

Study · Not a test of the peptide alone · 2025

5 results

Acid-Triggered Cascaded Responsive Supramolecular Peptide Alleviates Myocardial Ischemia‒Reperfusion Injury by Restoring Redox Homeostasis and Protecting Mitochondrial Function.

Liao X, Tang M, Li J, Guo R, Zhong C, Chen X, Zhang X, Mo H, Que D, Yu W, Song X, Li H, Cai Y, Yang P

Advanced healthcare materials20 Jan 2025Cited by 9 (Europe PMC)

PMID39831810 (opens in a new tab)DOI10.1002/adhm.202404319 (opens in a new tab)PepBankPUB-39831810
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone5

In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Elamipretide (SS-31).

  1. 01AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Mechanism

    The peptide-drug conjugate ISP bound Keap-1 with high affinity, activating Nrf2 and enhancing antioxidant capacity.

    In plain wordsIn lab tests, the conjugate bound Keap-1, switched on Nrf2 and boosted antioxidant capacity.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseKeap-1 binding and Nrf2 activation
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Cardiovascular

    Source sentences

    Summary
    bind to Keap-1 with high affinity, thereby activating Nrf2 and enhancing antioxidant capacity
    1 context sentence
    Summary · context
    In this study, a peptide‒drug conjugate OI-FFG-ss-SS31(ISP) is developed by integrating the Nrf2 activator 4-octyl itaconate (OI) and the mitochondria-targeting protective peptide elamipretide (SS31), and its therapeutic potential for myocardial I/R injury is explored.

    In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).

  2. 02AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Efficacy outcome

    Release of SS31 from the conjugate ISP improved mitochondrial function in myocardial ischemia-reperfusion injury.

    In plain wordsA conjugate that released SS31 improved mitochondrial function in a heart injury model.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseMitochondrial function
    Study

    n: not reported in source

    Outcome group
    Mitochondrial function · Cardiovascular

    Source sentences

    Summary
    the release of SS31 could improve mitochondrial function
    1 context sentence
    Summary · context
    In this study, a peptide‒drug conjugate OI-FFG-ss-SS31(ISP) is developed by integrating the Nrf2 activator 4-octyl itaconate (OI) and the mitochondria-targeting protective peptide elamipretide (SS31), and its therapeutic potential for myocardial I/R injury is explored.

    In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).

  3. 03AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Efficacy outcome

    Release of SS31 from the conjugate ISP reduced ROS in myocardial ischemia-reperfusion injury.

    In plain wordsA conjugate that released SS31 lowered reactive oxygen species in a heart injury model.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseReactive oxygen species
    Study

    n: not reported in source

    Outcome group
    Mitochondrial function · Cardiovascular

    Source sentences

    Summary
    the release of SS31 could improve mitochondrial function and reduce ROS
    1 context sentence
    Summary · context
    In this study, a peptide‒drug conjugate OI-FFG-ss-SS31(ISP) is developed by integrating the Nrf2 activator 4-octyl itaconate (OI) and the mitochondria-targeting protective peptide elamipretide (SS31), and its therapeutic potential for myocardial I/R injury is explored.

    In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).

  4. 04AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Efficacy outcome

    The peptide-drug conjugate ISP alleviated myocardial ischemia-reperfusion injury by restoring redox homeostasis.

    In plain wordsA conjugate containing SS31 reduced heart ischemia-reperfusion injury in the model tested.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseMyocardial ischemia-reperfusion injury
    Study

    n: not reported in source

    Outcome group
    Heart function · Cardiovascular

    Source sentences

    Summary
    Simultaneously, the release of SS31 could improve mitochondrial function and reduce ROS, ultimately providing a restoration of redox homeostasis to effectively alleviate myocardial I/R injury.
    1 context sentence
    Summary · context
    In this study, a peptide‒drug conjugate OI-FFG-ss-SS31(ISP) is developed by integrating the Nrf2 activator 4-octyl itaconate (OI) and the mitochondria-targeting protective peptide elamipretide (SS31), and its therapeutic potential for myocardial I/R injury is explored.

    In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).

  5. 05LabNot a test of Elamipretide (SS-31) aloneIn vitro (cell-free)Mechanism

    The peptide-drug conjugate ISP (4-octyl itaconate linked to SS31) self-assembled into nanofibers in an acidic microenvironment.

    In plain wordsIn lab tests, a conjugate of an Nrf2 activator and SS31 formed nanofibers in acid.

    Peptide
    Elamipretide (SS-31)
    Outcome
    Not applicableSelf-assembly into nanofibers in acidic microenvironment
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Cardiovascular

    Source sentences

    Summary
    ISP could self-assemble into nanofibers in response to the acidic microenvironment
    1 context sentence
    Summary · context
    In this study, a peptide‒drug conjugate OI-FFG-ss-SS31(ISP) is developed by integrating the Nrf2 activator 4-octyl itaconate (OI) and the mitochondria-targeting protective peptide elamipretide (SS31), and its therapeutic potential for myocardial I/R injury is explored.

    In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.